Among active 13F managers last quarter, 1 opened and 2 reduced; the largest holder to move was Renaissance Technologies LLC (−23%). No open-market insider trades in the last 180 days.
Funds lean out and no leg opposes.
6 tracked 13F filers disclose a position in XBIO as of the latest SEC 13F filings, a combined $461K in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies LLC | 137K | $368K | ▼−23% Reduced · −41K sh | Q1 2026 | |
| 2 | Geode Capital Management, LLC | 17K | $51K | ▼−19% Reduced · −4K sh | Q2 2026 | |
| 3 | Vanguard Capital Management LLC | 13K | $37K | ▲+88% Added · +6K sh | Q2 2026 | |
| 4 | SBI Securities Co., Ltd. | 1K | $3K | ▲New +1K sh | Q2 2026 | |
| 5 | Tower Research Capital LLC (TRC) | 806 | $2K | ▼−80% Reduced · −3K sh | Q1 2026 | |
| 6 | Darwin Wealth Management, LLC | 2 | $5 | —Held | Q2 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 1 fund opened a new position in XBIO, while 2 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Palantir Technologies Inc-APLTR | 3 funds | $1.1B |
| United Therapeutics CorpUTHR | 3 funds | $1.1B |
| Apple IncAAPL | 3 funds | $1.0B |
| Nvidia CorpNVDA | 3 funds | $980.4M |
| Micron Technology IncMU | 3 funds | $951.1M |
| Kinross Gold CorpKGC | 3 funds | $779.9M |
| Verisign IncVRSN | 3 funds | $700.9M |
| Exelixis IncEXEL | 3 funds | $589.2M |
| Sandisk CorpSNDK | 3 funds | $554.2M |
| Chevron CorpCVX | 3 funds | $446.3M |
| Roblox Corp -Class ARBLX | 3 funds | $406.5M |
| Carvana CoCVNA | 3 funds | $378.1M |
Ranked by how many of XBIO's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in XBIO.
No open-market insider transactions on file yet. Grants, gifts, and exercises live on the full insider page.
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 1 | 3 | – |
Insiders Form 4 open-market | 0 | 0 | $0 |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for XBIO
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/XBIO/capital-change-brief"
Use Arkolith's capital_change_brief for XBIO. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for XBIO. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.